For adverse event reporting please visithttps://contactazmedical.astrazeneca.com/
For full prescribing information, kindly refer to the approved package insert
FORXIGA® 10 mg (tablets) Reg. No. 46/21.2/0215. Each tablet contains the equivalent of 10 mg dapagliflozin as dapagliflozin propanediol. Contains lactose anhydrous.
PHARMACOLOGICAL CLASSIFICATION:A 21.2 Oral hypoglycaemics. INDICATIONS: FORXIGA ® is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as monotherapy or add-on combination therapy. WARNINGS AND PRECAUTIONS: Reports of metabolic acidosis, including ketoacidosis, which were serious life-threatening or fatal, in patients taking FORXIGA ®. Patients who present with signs and symptoms, should discontinue FORXIGA® and the patient should be promptly evaluated and managed accordingly
AstraZeneca Pharmaceuticals (Pty) Ltd. South Africa Reg. No. 1992/005854/07
Building 2, Northdowns Office Park, 17 Georgian Crescent West, Bryanston, 2191, South Africa.
Private Bag X23, Bryanston, 2021, South Africa.
Tel: 011 797-6000. Fax: 011 797-6001. www.astrazeneca.co.za.
Social media, review sites and other public internet sites are not the places for your comments and questions, however questions or comments can be answered by the AZ Medical Information Service at the following addresses: South African markets: SA.MEAMedinfo@astrazeneca.com
or call: 011-797 6000
For adverse event reporting please visit https://contactazmedical.astrazeneca.com/